Heidelberg Pharma AG

M&A Activity • Mar 28, 2014

News Details

Ad-hoc | 28 March 2014 17:18

WILEX AG: WILEX enters into licensing and development partnership for MESUPRON(R) in China with Link Health Group

WILEX AG / Key word(s): Alliance

28.03.2014 17:18

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

WILEX enters into licensing and development partnership for MESUPRON(R) in
China with Link Health Group

Munich, Germany, 28 March 2014 - WILEX AG (ISIN DE0006614720 / WL6 / FSE)
today announced that it has entered into a licensing and development
partnership for MESUPRON(R) with Link Health Co., Guangzhou, China. Link
Health will receive the exclusive licensing rights for the development and
marketing of MESUPRON(R) in China, Hong Kong, Taiwan and Macao.

Link Health will be responsible for performing and financing the entire
clinical development of MESUPRON(R) in China in all oncological
indications, including HER2-negative metastatic breast cancer and
non-metastatic pancreatic cancer, as well as for the regulatory process and
product marketing. To receive regulatory approval from the SFDA (Chinese
State Food and Drug Administration), the complete clinical development
programme from Phase I to Phase III must also be conducted in China, one of
the largest pharmaceutical markets with rapid growth rates. The data
generated may be used to support potential further development of
MESUPRON(R) in other key markets.

Under the agreement, WILEX will receive a signing fee and milestone
payments totalling more than 7 million Euro during clinical development in
the first four indications to be developed by Link Health as well as
staggered medium single digit royalties. The initial fees received by WILEX
under the cooperation will not materially influence the current cash reach
of the company.

---

Information and Explaination of the Issuer to this News:

Information on MESUPRON(R) and the uPA-programme
WILEX has developed with MESUPRON(R) (INN: Upamostat) a drug candidate to
inhibit the Urokinase Plasminogen Activator (uPA) system. The uPA system
has been shown to play a key role in tumour cell invasion and metastasis,
as well as in primary tumour growth, of various solid tumours. In the
Company's view, the uPA inhibitor MESUPRON(R) of WILEX can be considered as
a promising new non-cytotoxic approach in cancer therapy to prolong
progression free survival and to specifically block tumour metastasis in
solid cancers. Data from two Phase IIa trials (proof of concept) in locally
advanced pancreatic cancer (2010) and metastatic breast cancer (2012)
indications show the safety and activity of the drug candidate in
combination with chemotherapeutic agents.

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company's portfolio includes diagnostic and therapeutic
product candidates for the specific detection and targeted treatment of
various types of cancer based on antibodies and small molecules. Our aim is
out-licensing these clinical projects. The subsidiary Heidelberg Pharma
GmbH in Ladenburg, Germany, offers preclinical contract research services
and an antibody drug conjugate (ADC) technology platform. Our customers and
partners include leading international pharmaceutical companies. WILEX AG
is listed at the Frankfurt Stock Exchange: ISIN DE0006614720 / WKN 661472 /
Symbol WL6. More information is available at www.wilex.com.

Contact For press enquiries
WILEX AG MC Services AG
Sylvia Wimmer Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-29 Tel.: +49-89-210 228-40
Email: investors[at]wilex.com Mobil: +49 160 9360 3022
Grillparzerstr. 10, 81675 Munich, E-Mail: katja.arnold[at]mc-
Germany services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will', 'should', 'future', 'potential' or similar expressions or by
a general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

28.03.2014 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---